Nebulized fentanyl does not improve exercise capacity or dyspnoea in fibrosing interstitial lung disease
2025

Nebulized Fentanyl and Exercise in Lung Disease

Sample size: 8 publication 10 minutes Evidence: low

Author Information

Author(s): Charlotte Chen, John Kolbe, Julian F. R. Paton, James P. Fisher

Primary Institution: University of Auckland

Hypothesis

Can nebulized fentanyl alleviate dyspnoea and improve exercise tolerance during incremental cardiopulmonary exercise tests in patients with fibrosing interstitial lung disease?

Conclusion

Nebulized fentanyl did not improve exercise endurance time or dyspnoea in patients with fibrosing interstitial lung disease, although it did reduce minute ventilation during exercise.

Supporting Evidence

  • Fentanyl did not increase exercise endurance time compared to placebo.
  • Minute ventilation was reduced with fentanyl, but the reduction was not clinically significant.
  • Heart rate was lower after fentanyl compared to placebo during rest and exercise.

Takeaway

The study tested if a medicine called fentanyl could help people with lung disease breathe better during exercise, but it didn't really help.

Methodology

This was a randomized, single-blind, placebo-controlled crossover study where participants performed exercise tests after inhaling either fentanyl or saline.

Potential Biases

There may be risks of bias due to the small sample size and the lack of an age-matched control group.

Limitations

The sample size was small, and the study may not have had enough power to detect differences in outcomes.

Participant Demographics

Participants were eight individuals with stable fibrosing interstitial lung disease, average age 71 years, with no current smokers.

Statistical Information

P-Value

0.250

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1113/EP092123

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication